Ordinarily, cash dividends are great. They can be the main reason to even buy shares.
But with the notable exception of the “marijuana REIT,” Innovative Industrial Properties Inc. (NYSE: IIPR), the cannabis industry is a little different.
In cannabis right now, a dividend could conceivably be a red flag.
When you own part of a cannabis company, you own a piece of an industry that's set to grow faster than any other industry has for generations.
But that claim doesn't come with a cash payout… yet.
Here's what I mean…
It's All About Growth, Growth, Growth
Cannabis industry growth will come because the gap between legal and illegal marijuana sales spans hundreds of billions of dollars, and the legalization wave means revenue has to grow incredibly fast to fill it.
But filling the void between existing legal and illegal sales is not the sole driver of growth.
The Next American Aristocracy is expected to be fueled by today's cannabis boom. If you take advantage now, you could enjoy the kind of wealth “that lasts generations.” Click here to see for yourself…
Legalization spurs the emergence of entirely new markets for cannabis products. And these will spring up faster than anyone thought possible.
Toss these new markets into the mix, and before you know it, total legal-market sales could exceed today's illegal sales by two to three times. Just keeping pace with the soaring demand for cannabis will drive the best companies' annual revenue growth past 80% for years to come.
And once you see all the moneymaking opportunities staring them in the face, you'll be glad to own a cannabis stock that doesn't cut you a dividend check…
Here's What Will Drive That Growth
Cannabis sales approached $350 billion last year, mostly from traditional marijuana, of which only about $20 billion were legal. Tapping into these existing illegal marijuana markets around the globe as they turn legal is just one of the many ways cannabis CEOs can launch profits.
High-growth profits will also come from the emerging medical marijuana market.
Marijuana for medical use is gaining wide acceptance both here and abroad, and public awareness of the powerful treatment possibilities of CBD grows daily. Given all the conditions that THC and CBD can treat, it's hard to overstate just how big this market could get.
In the United States alone, people spent $18 billion on over-the-counter pain medication in 2018. When you add in prescription-based opioid sales, those figures double. On a global basis, sales of pain medication could reach four times that number, and it's clear that sales of medical marijuana could displace much of that market.
Around the globe, over 1 billion people suffer from any of the 10 key medical conditions for which cannabis is being prescribed as a treatment. The 20% using it therapeutically makes for a market of 200 million patients that didn't buy marijuana before. And the cost to treat these conditions ranges from a few hundred bucks to tens of thousands of dollars.
So, spending an average of $1,000 each year to treat these conditions makes for another $200 billion market in and of itself.
To this, we can add the potential for patentable cannabinoid-based pharmaceutical drugs. Prescription drugs will make up a $1 trillion market by 2020, and we can expect customized cannabinoid compounds to soon start taking a sizeable chunk out of this profit-rich market.
And don't forget that I hailed 2019 as the “Year of CBD.” Nutraceuticals, sports medicine, and health and beauty products will demand massive production of CBD. The 2018 Farm Bill and removal of CBD from the Controlled Substances Act has also created tremendous upside for CEOs doing whatever it takes to scale up their businesses.
But there is an unknown here, albeit an “all upside” unknown. No one really knows how many buyers the industry could attract once cannabis is legal at the federal level. Best estimates point to… quite a lot. Cannabis-infused edibles, beverages, vapes, and other methods of recreational use could develop into a massive market as marijuana goes mainstream.
Given how quickly things develop in cannabis, we'll know soon enough – and cannabis company executives know the cannabis market will swell far too big to waste precious capital on dividends.
That brings us to the crux of the issue.
Cannabis CEOs Need All the Cash They Can Possibly Get
Now, dividends matter to many investors. Whether they reinvest the money or spend it, the income received is critical to building wealth.
But the companies paying dividends don't do so out of regard for what the investor wants. To management, dividend policy represents a kind of capital-planning tool… Full story at Money Morning
Meet the Three Tiny Cannabis Companies That Could Set You Up for Life
Marijuana legalization is currently in full swing – and folks literally can't get enough. Demand is so insane, one Canadian retailer sold $50,000 worth of product in the first hour. We've never seen anything like this… and the profit potential at stake is great enough to hand you $2 million by this time next year. Go here for details.